TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05049811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mini program
Description: To design, construct, and test the mini program in patients managing cancer pain

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional pharmaceutical care
Description: Regular education includes medication guidance from doctors, nurses and pharmacists.
Study: NCT05739929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG Oral Tablet
Description: 0.5 mg colchicine tablets twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets twice daily
Study: NCT05796440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-201
Description: Administered orally once daily
Study: NCT05921526

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound
Description: Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray (digital images)
Description: Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
Study: NCT04148417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solo+ Tympanostomy Tube Device
Description: The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
Study: NCT04753203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib plus Capecitabine combination
Description: Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
Study: NCT05429372

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PF-06939926
Description: All participants will receive a single dose of PF-06939926 on Day 1.
Study: NCT05333458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT06254625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiome
Description: Fecal microbiome transplantation from a healthy donor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Place capsules
Study: NCT04890184

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grape juice
Description: grape juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no intervention
Study: NCT05557708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 212-Lead Pentixather
Description: Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 203-Lead Pentixather SPECT/CT
Description: Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
Study: NCT04708522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Control - Equal Breathing Technique
Description: The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Mindfulness Exercise
Description: The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
Study: NCT06397846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample
Description: blood sample will be collected at baseline
Study: NCT06004479

Intervention type: OTHER
Intervention: Carotenoid Intake
Description: Carotenoid intake assess by 24 hour dietary recalls

Intervention type: OTHER
Intervention: Carotenoid Intake
Description: Carotenoid intake assess by 24 hour dietary recalls

Intervention type: OTHER
Intervention: Serum carotenoid concentration
Description: Serum total carotenoid concentration

Intervention type: OTHER
Intervention: Serum carotenoid concentration
Description: Serum total carotenoid concentration
Study: NCT04628013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noxious Electrical Stimulation (NxES)
Description: The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
Study: NCT05729217

Intervention type: OTHER
Intervention: SBQ-LC survey
Description: Symptom burden questionnaires of Long COVID

Intervention type: OTHER
Intervention: SBQ-LC survey
Description: Symptom burden questionnaires of Long COVID

Intervention type: OTHER
Intervention: SBQ-LC survey
Description: Symptom burden questionnaires of Long COVID
Study: NCT05903196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mygen V-1000 RF system
Description: The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
Study: NCT06457984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium nutritional supplementation
Description: Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium nutritional supplementation
Description: Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium nutritional supplementation
Description: Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
Study: NCT05236491

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: Participants are to receive a booster dose of a COVID-19 vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: Participants are to receive a booster dose of a COVID-19 vaccine.
Study: NCT05586113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-day Tegoprazan bismuth-containing quadruple therapy
Description: 10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-day Tegoprazan bismuth-containing quadruple therapy
Description: 10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
Study: NCT05483387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with HBS 2 Resorb Mg
Description: Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
Study: NCT06406699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Reprocessing Therapy (PRT)
Description: PRT is a psychological intervention for chronic pain patients with a primary nociplastic component. PRT aims to help patients reconceptualize their pain as a non-dangerous signal that is not indicative of tissue pathology or structural abnormality. Through decreasing the threat level of their chronic pain, the pain itself can also resolve.
Study: NCT03643042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
Study: NCT05946070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONKOSIS
Description: ONKOSIS is a mobile phone-based monitoring system in the management of chemotherapy-related symptoms
Study: NCT05713266

Intervention type: DEVICE
Intervention: MouthLabTM
Description: Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
Study: NCT06011239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-building processes
Description: All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic.
Study: NCT06555198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot(at)Work intervention
Description: Foot(at)Work intervention is targeted for nurses working in clinical settings to promote their competence in lower extremity health self-care.
Study: NCT06553794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastroscopy with duodenal mucosal tissue biopsies
Description: Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 loading day, 1 maintenance day) and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed.
Study: NCT04769869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Study: NCT05128019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICIT
Description: Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
Study: NCT05582057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths to Grow: Preteen
Description: An online, strength based parenting program for parents of preteens (aged 9-14).
Study: NCT05407142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS
Description: Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml.

Intervention type: OTHER
Group type: OTHER
Intervention: The data from volunteers from the control group
Description: Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
Study: NCT05207137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone call about vaccination
Description: Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
Study: NCT05303935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 50 MG
Description: A single dose of 50mg of quetiapine taken at bedtime for one night.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
Study: NCT05276505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy Tablet
Description: Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy Tablet
Description: Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
Study: NCT06457620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Each participant received conventional physiotherapy at the clinic as a part of their management plan. Group A exercise was five times a week for thirty minutes, beginning on the third day after total knee arthroplasty (TKA). The program aimed to improve leg strength, core stability, balance, and overall performance through exercise instructions. The baseline evaluation was completed one day before the TKA, and the posttest was completed four weeks after the TKA.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Physical Preatment
Description: Each participant got traditional physical treatment during a video conference as part of telerehabilitation. The physiotherapy assistant contacted Group B to arrange a virtual follow-up clinic appointment via Zoom or WhatsApp, along with a 4-week program. We inquired about the patient's level of satisfaction with their TKR procedure. The patient was informed that clinical photos were taken, and the video call was to be recorded. Before the virtual clinic, each patient's verbal agreement was acquired. With workout instructions, the program pursued to enhance leg strength, core stability, balance, and overall performance. The posttest was conducted four weeks after the TKA, and the baseline assessment was finished one day before the procedure.
Study: NCT05442203

Intervention type: DEVICE
Group type: OTHER
Intervention: Zio Patch Monitor
Description: Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiogram
Description: Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
Study: NCT05184699

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food supplement Endocalyx
Description: Patients with psoriatic disease will be randomized to receive food supplement Endocalyx for 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with psoriatic disease will be randomized to receive placebo for 4 months.
Study: NCT06142188

Intervention type: BIOLOGICAL
Intervention: Relmacabtagene Autoleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Study: NCT04862962

Intervention type: DRUG
Intervention: Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
Description: Oral Tablets 10 mg/10 mg or 20 mg/10 mg
Study: NCT05430841

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG, 18F-AlF-FAPI PET/CT
Description: Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
Study: NCT04953650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
Study: NCT05177952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Resistance training with BFR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Resistance Training with no BFR
Study: NCT05012319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: to be given as a treatment
Description: Nitric Oxide Nasal Spray Enovid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: to be given as a treatment
Description: Nitric Oxide Nasal Spray Enovid
Study: NCT06121830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 20mg
Description: DWP14012 20mg, tablet, orally, once daily for up to 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 40mg
Description: DWP14012 40mg, tablet, orally, once daily for up to 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablet, orally, once daily for up to 4 weeks
Study: NCT04769869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
Study: NCT06373445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation active stimulation
Description: This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation sham stimulation
Description: This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.